E Fund CSI 300 Pharmaceutical and Health Exchange-traded Open-ended Index Securities Investment Fund (abbreviation: E Fund CSI 300 Pharmaceutical ETF, code 512010) announced its latest net value on November 22, down 3.79%.
E Fund CSI 300 Pharmaceutical ETF was established on September 23, 2013, and its performance is based on the CSI 300 Pharmaceutical and Health Index. The fund has returned 48.20% since its inception, -9.96% this year, -2.53% over the past month, -14.47% over the past year, and -43.16% over the last three years. In the past year, the fund ranked 3070/3274 in its peer group.
The fund manager is Yu Haiyan. Yu Haiyan has managed (or intends to manage) the fund since 21 August 2013 and has returned 48.2% during her tenure.
According to the latest periodic report, the fund's top 10 heavy stocks are as follows:
| stock symbol | ,stock name | ,position ratio | , number of shares held (shares). | Market value of the position (RMB). |
| 600276 | Hengrui Pharmaceutical | , 16.89%, | 69726906 | 3.647 billion |
| , 300760 | ,Mindray Medical | , 12.86%, | 9477893 | 2.777 billion |
| 603259 | WuXi AppTec | 9.50% | 39190020 | 2.052 billion |
| 600436 | Pien Tze Huang | 5.65% | 4716064 | 1.219 billion |
| 300015 | Aier Ophthalmology | 5.37% | 72827837 | 1.159 billion |
| 000538 | Yunnan Baiyao | 3.93% | 13928166 | 850 million |
| 688271 | United Imaging Medical | 3.08% | 5201691 | 666 million |
| 002252 | Shanghai RAAS | 3.04% | 83027035 | 656 million |
| 002001 | Xinhecheng | 3.03% | 28960377 | 654 million |
| 300122 | Zhifei Biotech | 2.89% | 18694189 | 624 million |
Ticker Name
Percentage Change
Inclusion Date
